Infectious Disease

Vaccine manufacturer announces plans to meet U.S. demand for flu vaccine

Published in TB and Outbreaks Week, January 7th, 2003

Aventis Pasteur has announced the company is committed to meeting U.S. demand for Fluzone influenza virus vaccine following Wyeth's recent announcement to discontinue production of its influenza vaccine.

Aventis Pasteur's Swiftwater, Pennsylvania, facility currently produces about half the influenza vaccine used in the U.S. Aventis Pasteur globally produces more than half the influenza vaccine used in the world.

Aventis Pasteur recently announced an $80 million investment to increase filling and formulation capacity at its Swiftwater facility. The company is in the process of evaluating a still greater expansion within the next several years to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2003-01-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry